Pediatric Pharmacy Specialty Recertification Literature Study: Module 1A-B (Cert # L219142)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/17/2021
Content Release Date: 04/14/2021
Expiration Dates: 10/19/2021
Activity Type: Application-based
CE Credits: 10.00 hours (BPS and ACPE)
Activity Fee: $55 (ASHP member); $110 (non-member)

Accreditation for Pharmacists

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

Target Audience

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS).

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice and includes a short video for enhanced learning and understanding. 

Module 1A: Hematology/Oncology: This module focuses on hematology and oncology issues such as methotrexate intensification in T-cell ALL; voxelotor in sickle cell disease; cardioprotectiveness of dexrazosane in AML; and selumetinib in refractory low-grade glioma. 

Module 1B: General Pediatrics/NICU: This module focuses on development of the KIDs List, a list of drugs potentially inappropriate for use in pediatric patients; levetiracetam vs. phenobarbital for neonatal seizures; neuroprotectiveness of erythropoietin in preterm infants; and oral vitamin A supplementation in very low birth weight neonates.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.  

Recertification Credit*

Board certified pharmacists are eligible to receive up to 10 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

Pediatric Pharmacy Recertification Literature Study Module 1A: Hematology / Oncology

0204-0000-21-967-H01-P

5

76%

Pediatric Pharmacy Recertification Literature Study Module 1B: General Pediatrics / NICU

0204-0000-21-968-H01-P

5

76%

 

Articles and Learning Objectives

Module 1A: Hematology/Oncology
ACPE number: 0204-0000-21-967-H01-P 

Hematology/Oncology: This module focuses on hematology and oncology issues such as methotrexate intensification in T-cell ALL; voxelotor in sickle cell disease; cardioprotectiveness of dexrazosane in AML; and selumetinib in refractory low-grade glioma. 

Fangusaro J, Onar-Thomas A, Young Poussaint T et al. Selumetinib in paediatric patients with BRAF-aberrant or neuro bromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019 Jul; 20(7):1011-1022. 

Learning Objectives:

  • Describe the study of selumetinib in pediatric patients with low-grade glioma.
  • Develop recommendations for the use of selumetinib in pediatric patients with low-grade glioma. 

Getz KD, Sung L, Alonzo TA et al. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients with Acute Myeloid Leukemia: A Report From the Children’s Oncology Group. J Clin Oncol. 2020 Jul 20; 38(21):2398–2406. 

Learning Objectives:

  • Describe the Children's Oncology Group trial AAML1031 of dexrazoxane in pediatric patients with acute myeloid leukemia (AML).
  • Develop recommendations for the use of dexrazoxane for cardioprotection in pediatric patients receiving frontline treatment for acute myeloid leukemia (AML). 

Winter SS, Dunsmore KP, Devidas M et al. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018 Oct 10; 36(29):2926-2934. 

Errata—J Clin Oncol. 2019 Mar 20; 37(9):761. 

Learning Objectives:

  • Describe the Children’s Oncology Group AALL0434 study in children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) comparing (1) Capizzi style intravenous methotrexate (C-MTX) with escalating intravenous methotrexate (MTX) without leucovorin plus two doses of pegaspargase and (2) high-dose MTX (HDMTX) with leucovorin rescue without pegaspargase.
  • Develop recommendations for methotrexate treatment intensification in children and young adults with T-cell acute lymphoblastic leukemia (T-ALL). 

Vichinsky E, Hoppe CC, Ataga KI et al.  A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 Aug 8; 381(6):509-519. 

Learning Objectives:

  • Describe the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) study of voxelotor in adolescents and adults with sickle cell disease.
  • Develop recommendations for the use of voxelotor in patients with sickle cell disease.

Module 1B: General Pediatrics / NICU
ACPE Number: 0204-0000-21-968-H01-P 

General Pediatrics/NICU: This module focuses on development of the KIDs List, a list of drugs potentially inappropriate for use in pediatric patients; levetiracetam vs. phenobarbital for neonatal seizures; neuroprotectiveness of erythropoietin in preterm infants; and oral vitamin A supplementation in very low birth weight neonates. 

Juul SE, Comstock BA, Wadhawan DE et al. A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. N Engl J Med. 2020; 382:233-43. 

Learning Objectives:

  • Describe the Preterm Erythropoietin Neuroprotection Trial (PENUT).
  • Develop recommendations for the use of early erythropoietin in extremely preterm infants. 

Meyers RS, Thackray J, Matson KL et al.  Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020; 25(3):175–191. 

Learning Objectives:

  • Describe the KIDs list of drugs that are potentially inappropriate for use in pediatric patients.
  • Develop recommendations for the use of medications on the KIDs list of drugs that are potentially inappropriate for use in pediatric patients. 

Sharpe C, Reiner GE, Davis SL et al. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics. 2020;145(6):e20193182 

Learning Objectives:

  • Describe the NEOLEV2 study comparing the efficacy and safety of levetiracetam with phenobarbital as first-line treatment for neonatal seizures.
  • Develop recommendations for the treatment of seizures in neonates. 

Basu S, Khanna P, Srivastava R, Kumar A. Oral vitamin A supplementation in very low birth weight neonates: a randomized controlled trial. European Journal of Pediatrics. (2019); 178:1255–1265. Erratum:  Correction to: Oral vitamin A supplementation in very low birth weight neonates: a randomized controlled trial. Basu S, Khanna P, Srivastava R, Kumar A. Eur J Pediatr. 2019 Sep; 178(9):1469. doi: 10.1007/s00431-019-03423-7. PMID: 31338676 

Learning Objectives:

  • Describe the study of early postnatal vitamin A supplementation in very low birth weight neonates with respiratory distress.
  • Develop recommendations for the use of early postnatal vitamin A supplementation in very low birth weight neonates with respiratory distress. 

Faculty

Full Faculty Bios

Joshua Elder, Pharm.D., BCPS, BCOP
Clinical Specialist - Pediatric Hematology/Oncology/Stem Cell Transplant
Norton Children's Hospital
Louisville, Kentucky 

Erin Martin, Pharm.D., BCPS, BCPPS
Pediatric Pharmacy Clinical Specialist
University of Missouri Healthcare
Women's and Children's Hospital
Columbia, Missouri 

Alexandra Oschman, Pharm.D., BCPPS
NICU Clinical Pharmacy Specialist
Children’s Mercy Kansas City
Adjunct Clinical Assistant Professor
University of Missouri-Kansas City School of Pharmacy
Kansas City, Missouri 

Jennifer Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York 

Tara Wright, Pharm.D., BCPPS, BCOP
Hematology/Oncology Pharmacist
Seattle Children's Hospital
Seattle, Washington 

Content Matter Experts

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FPPAG
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Clinical Specialist, Pediatric Critical Care
The Children's Hospital at OU Medical Center
Oklahoma City, Oklahoma 

Jamie L. Miller, Pharm.D., BCPPS, BCPS
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma 

Jennifer L. Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York 

Reviewers

Michelle C. Abalos, Pharm.D.
Susan R. Dombrowski, B.S.Pharm., M.S.
Kristi N. Hofer, Pharm.D. 

Field Testers

Hakeem  Abayomi, B.S., Pharm.D., BCPS., BCPPS
Jessica Biggs, Pharm.D., BCPPS
Deneshia Brodbeck, R.Ph., BCPPS
Octavio Casanova, Pharm.D., BCPPS
Allison Chung, Pharm.D.
Melissa Cook, Pharm.D., BCPPS
Melissa Cwiklinski, Pharm.D., BCPPS
Tasnim Dawoud, Pharm.D., MSc.
Heather Dedman, BSP, BCPPS
Debra Determan, Pharm.D., BCPPS
Kristen Finical, Pharm.D., BCPPS
Nozomi Giese Kim, Pharm.D., BCPS, BCPPS
Gina Gries, Pharm.D., BCPS, BCPPS
Sarah Hale, Pharm.D., BCPPS
Brent Hall, Pharm.D., BCPPS
Aaron Harthan, Pharm.D., BCPPS
Pui Man (Julia) Ho, Pharm.D., BCPPS
Kaitlin Hughes, Pharm.D., BCPPS
Jason Koury, Pharm.D., BCPPS
Megan Kroll, Pharm.D., BCPPS, CNSC
Biljana Lanier, B.S.Pharm., BCPPS
Yi-Shiu Lin, BCPPS
Man Soi Lo, BCCCP
Linda Marshall, Pharm.D., BCPPS
Danielle McDonald, Pharm.D., BCPPS
Julie Miller, Pharm.D, BCPPS
Kati Munson, Pharm.D., BCPPS
Hong Nguyen, Pharm.D., BCPPS
Kristen Nichols, Pharm.D., BCPS, BCPPS, BCIDP
Lucas Orth, Pharm.D., BCPPS
Seema Patel, Pharm.D., BCPPS
Margaret Poisson, Pharm.D, BCPPS
Michael Raschka, Pharm.D., BCPPS
Karla Resendiz, Pharm.D. BCPPS
Alyssa Wu, Pharm.D., BCPPS
Kelvin Xu, Pharm.D., BCPPS, BSC (pharm) 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Jennifer Thackray: Consultant, Wolters Kluwer;spouse: Employee, Equashield
  • All other planners, presenters, reviewers, ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP.